Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML

The therapeutic approach to Chronic Myeloid Leukemia (CML) has changed since the advent of the tyrosine kinase inhibitor (TKI) imatinib, which was then followed by the second generation TKIs dasatinib, nilotinib, and, finally, by ponatinib, a third-generation drug. At present, these therapeutic opti...

Full description

Bibliographic Details
Main Authors: Francesca Carofiglio, Antonio Lopalco, Angela Lopedota, Annalisa Cutrignelli, Orazio Nicolotti, Nunzio Denora, Angela Stefanachi, Francesco Leonetti
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:International Journal of Molecular Sciences
Subjects:
chronic myeloid leukemia
tyrosine kinase inhibitors
pediatric age
imatinib
dasatinib
nilotinb
Online Access:https://www.mdpi.com/1422-0067/21/12/4469

Internet

https://www.mdpi.com/1422-0067/21/12/4469

Similar Items